174 related articles for article (PubMed ID: 26037932)
1. Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Hoffmann A; Schmidtke M; Clement B
J Pharm Sci; 2015 Sep; 104(9):3208-19. PubMed ID: 26037932
[TBL] [Abstract][Full Text] [Related]
2. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Koch O; Seidel N; Schmidtke M; Clement B
J Med Chem; 2014 Feb; 57(3):759-69. PubMed ID: 24422530
[TBL] [Abstract][Full Text] [Related]
3. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
Ye D; Shin WJ; Li N; Tang W; Feng E; Li J; He PL; Zuo JP; Kim H; Nam KY; Zhu W; Seong BL; No KT; Jiang H; Liu H
Eur J Med Chem; 2012 Aug; 54():764-70. PubMed ID: 22795831
[TBL] [Abstract][Full Text] [Related]
5. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
[TBL] [Abstract][Full Text] [Related]
6. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
[TBL] [Abstract][Full Text] [Related]
7. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
Tarbet EB; Hamilton S; Vollmer AH; Luttick A; Ng WC; Pryor M; Hurst BL; Crawford S; Smee DF; Tucker SP
J Antimicrob Chemother; 2014 Aug; 69(8):2164-74. PubMed ID: 24777908
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
9. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
Li W; Escarpe PA; Eisenberg EJ; Cundy KC; Sweet C; Jakeman KJ; Merson J; Lew W; Williams M; Zhang L; Kim CU; Bischofberger N; Chen MS; Mendel DB
Antimicrob Agents Chemother; 1998 Mar; 42(3):647-53. PubMed ID: 9517946
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
Ding Y; Dou J; Teng Z; Yu J; Wang T; Lu N; Wang H; Zhou C
Arch Virol; 2014 Dec; 159(12):3269-78. PubMed ID: 25078390
[TBL] [Abstract][Full Text] [Related]
12. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
[TBL] [Abstract][Full Text] [Related]
14. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
Mishin VP; Sleeman K; Levine M; Carney PJ; Stevens J; Gubareva LV
Antiviral Res; 2014 Jan; 101():93-6. PubMed ID: 24239666
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
[TBL] [Abstract][Full Text] [Related]
16. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Bauer K; Richter M; Wutzler P; Schmidtke M
Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
[TBL] [Abstract][Full Text] [Related]
17. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H; Kawai N
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
19. Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.
Arns S; Tan J; Sun S; Galey A; Zisman N; Ross F; Udechukwu J; Dercho S; Gusti V; Paquette J; Webb M; Bourque E; Withers SG; Liggins R
Bioorg Med Chem Lett; 2015 Jun; 25(12):2505-9. PubMed ID: 25980910
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
